Assembly Biosciences Reports Positive Year-End 2025 Financial Results and Advances in Herpes Virus Programs
Assembly Biosciences, Inc. (ASMB) announced its financial results for the quarter and year ended December 31, 2025, highlighting significant progress in its antiviral programs, particularly in the area of herpes simplex virus (HSV). The company’s CEO and President, Jason Okazaki, stated that 2025 was a “momentous year” and anticipates continued strong performance in the year ahead.
Key Financial Highlights for 2025
- Revenue: Total revenues from collaborative research with Gilead Sciences reached $72.3 million in 2025, a substantial increase compared to $28.5 million in 2024.
- Cash Reserves: As of December 31, 2025, Assembly Biosciences held $248.1 million in cash, cash equivalents, and marketable securities, providing financial runway through 2028. This is an increase from $232.6 million as of September 30, 2025, and $112.1 million as of December 31, 2024.
- Research & Development: Investment in research and development increased to $64.8 million in 2025, up from $55.9 million in 2024, driven by advancements in the herpes simplex virus (HPI) programs.
- Net Loss: The company reported a net loss attributable to common shareholders of $6.1 million, or $0.55 per share, in 2025, an improvement from a loss of $40.2 million, or $6.69 per share, in 2024.
- Total Equity: As of the end of 2025, total shareholder equity was $267.51 million.
Progress in Antiviral Programs
A key achievement in 2025 was Gilead Sciences’ decision to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor (HPI) programs, including ABI-5366 and ABI-1179, following positive Phase 1b interim data. This licensing agreement included an option fee of $35 million for Assembly Bio. Positive Phase 1b interim data was also announced for ABI-1179, evaluating two weekly dose cohorts for recurrent genital herpes, and for ABI-5366.
Leadership
Jason Okazaki has served as President and CEO of Assembly Biosciences since 2020. Prior to joining Assembly Bio, he held the position of Senior Vice President, Legal and Assistant Secretary at Gilead Sciences for 14 years, where he led a global legal team and oversaw corporate governance and SEC reporting [1]. He also has experience in mergers and acquisitions from his time at Skadden, Arps, Slate, Meagher & Flom LLP.
About Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing innovative treatments for serious viral diseases, including herpes virus, hepatitis B virus, and hepatitis delta virus infections [2].
Disclaimer: This article is based on publicly available information as of March 20, 2026, and should not be considered financial advice.